These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20869831)

  • 1. Stability of Myrmecia pilosula (Jack Jumper) Ant venom for use in immunotherapy.
    Wiese MD; Davies NW; Chataway TK; Milne RW; Brown SG; Heddle RJ
    J Pharm Biomed Anal; 2011 Jan; 54(2):303-10. PubMed ID: 20869831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myrmecia pilosula (Jack Jumper) ant venom: validation of a procedure to standardise an allergy vaccine.
    Wiese MD; Milne RW; Davies NW; Chataway TK; Brown SG; Heddle RJ
    J Pharm Biomed Anal; 2008 Jan; 46(1):58-65. PubMed ID: 17933477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing the quality of Myrmecia pilosula (Jack Jumper) ant venom for use in in vitro and in vivo diagnoses of allergen sensitization and in allergen immunotherapy.
    Wanandy T; Dwyer HE; McLean L; Davies NW; Nichols D; Gueven N; Brown SGA; Wiese MD
    Clin Exp Allergy; 2017 Nov; 47(11):1478-1490. PubMed ID: 28756642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterisation of major peptides in 'jack jumper' ant venom by mass spectrometry.
    Davies NW; Wiese MD; Brown SG
    Toxicon; 2004 Feb; 43(2):173-83. PubMed ID: 15019477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic analysis of Myrmecia pilosula (jack jumper) ant venom.
    Wiese MD; Chataway TK; Davies NW; Milne RW; Brown SG; Gai WP; Heddle RJ
    Toxicon; 2006 Feb; 47(2):208-17. PubMed ID: 16376960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myrmecia pilosula (Jack Jumper) ant venom: identification of allergens and revised nomenclature.
    Wiese MD; Brown SG; Chataway TK; Davies NW; Milne RW; Aulfrey SJ; Heddle RJ
    Allergy; 2007 Apr; 62(4):437-43. PubMed ID: 17362256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards complete identification of allergens in Jack Jumper (Myrmecia pilosula) ant venom and their clinical relevance: An immunoproteomic approach.
    Wanandy T; Wilson R; Gell D; Rose HE; Gueven N; Davies NW; Brown SGA; Wiese MD
    Clin Exp Allergy; 2018 Sep; 48(9):1222-1234. PubMed ID: 29975807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of jack-jumper ant (Myrmecia pilosula) venom allergens.
    Ford SA; Baldo BA; Weiner J; Sutherland S
    Clin Exp Allergy; 1991 Mar; 21(2):167-71. PubMed ID: 2043985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy.
    Wanandy T; Honda-Okubo Y; Davies NW; Rose HE; Heddle RJ; Brown SGA; Woodman RJ; Petrovsky N; Wiese MD
    J Pharm Biomed Anal; 2019 Aug; 172():1-8. PubMed ID: 31009889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of an IgE-binding determinant of the major allergen Myr p I from the venom of the Australian jumper ant Myrmecia pilosula.
    Donovan GR; Street MD; Baldo BA; Alewood D; Alewood P; Sutherland S
    Biochim Biophys Acta; 1994 Jan; 1204(1):48-52. PubMed ID: 7508264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilosulin 5, a novel histamine-releasing peptide of the Australian ant, Myrmecia pilosula (Jack Jumper Ant).
    Inagaki H; Akagi M; Imai HT; Taylor RW; Wiese MD; Davies NW; Kubo T
    Arch Biochem Biophys; 2008 Sep; 477(2):411-6. PubMed ID: 18544336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of Jack Jumper ant venom immunotherapy: our 25 years' experience.
    Wanandy T; Le TA; Lau WY; Wiese MD; Heddle RJ; Brown SGA
    Intern Med J; 2023 Sep; 53(9):1716-1721. PubMed ID: 37743244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of anaphylaxis with ant venom immunotherapy.
    Brown SG; Heddle RJ
    Curr Opin Allergy Clin Immunol; 2003 Dec; 3(6):511-6. PubMed ID: 14612677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of jumper ant (Myrmecia pilosula) venom allergens: post-translational processing of allergen gene products.
    Donovan GR; Street MD; Tetaz T; Smith AI; Alewood D; Alewood P; Sutherland SK; Baldo BA
    Biochem Mol Biol Int; 1996 Aug; 39(5):877-85. PubMed ID: 8866004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilosulins: a review of the structure and mode of action of venom peptides from an Australian ant Myrmecia pilosula.
    Wanandy T; Gueven N; Davies NW; Brown SG; Wiese MD
    Toxicon; 2015 May; 98():54-61. PubMed ID: 25725257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Separation of jumper ant (Myrmecia pilosula) venom allergens: a novel group of highly basic proteins.
    Donovan GR; Street MD; Baldo BA
    Electrophoresis; 1995 May; 16(5):804-10. PubMed ID: 7588566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular cloning and characterization of the major allergen Myr p II from the venom of the jumper ant Myrmecia pilosula: Myr p I and Myr p II share a common protein leader sequence.
    Street MD; Donovan GR; Baldo BA
    Biochim Biophys Acta; 1996 Feb; 1305(1-2):87-97. PubMed ID: 8605256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ant allergy in Asia and Australia.
    Shek LP; Ngiam NS; Lee BW
    Curr Opin Allergy Clin Immunol; 2004 Aug; 4(4):325-8. PubMed ID: 15238800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania.
    Brown SG; Franks RW; Baldo BA; Heddle RJ
    J Allergy Clin Immunol; 2003 Jan; 111(1):187-92. PubMed ID: 12532117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immediate allergic reactions to Myrmecia ant stings: immunochemical analysis of Myrmecia venoms.
    Street MD; Donovan GR; Baldo BA; Sutherland S
    Clin Exp Allergy; 1994 Jun; 24(6):590-7. PubMed ID: 7922779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.